Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. develops clinical-stage biotechnology programs for cancer and rare diseases. Company news centers on TARA-002, an investigational cell-based therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, including updates from the ADVANCED-2 trial in BCG-Unresponsive and BCG-Naïve NMIBC patient groups.
Recurring updates also cover IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving long-term parenteral support. Other company announcements include clinical-conference presentations, FDA designation updates, financial results, equity compensation grants under Nasdaq rules, and capital-raising activity tied to Protara's development-stage pipeline.
Protara Therapeutics (Nasdaq: TARA) will present interim data from Cohort A of the Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve non-muscle invasive bladder cancer (NMIBC) at the 26th Annual Meeting of the Society of Urologic Oncology in Phoenix, Dec 2–5, 2025.
The poster will report updated safety and efficacy from 31 enrolled BCG-naïve patients, the majority having reached the six-month evaluation. ADVANCED-2 (NCT05951179) is an open-label Phase 2 trial evaluating intravesical TARA-002 in CIS (± Ta/T1) patients with BCG-unresponsive (~100) or BCG-naïve (31) cohorts. Poster details: Poster 149, Session: Bladder Cancer, Dec 4, 2025, 2:30–3:30 p.m. CT.
Protara Therapeutics (Nasdaq: TARA) reported third quarter 2025 results and provided a program update on November 10, 2025. The company had $133.6 million in cash, cash equivalents and marketable debt securities as of September 30, 2025, which it expects will fund operations into mid-2027. Key clinical milestones: interim readout from the Phase 2 STARBORN-1 pediatric LMs trial expected in 4Q 2025; interim analysis of ~25 six-month evaluable BCG-unresponsive NMIBC patients in ADVANCED-2 expected in 1Q 2026; first dosing in THRIVE-3 registrational IV Choline Chloride trial now expected by year-end 2025.
Q3 expenses rose; net loss was $13.3M ($0.31/share).
Protara Therapeutics (Nasdaq: TARA) was named a BioSpace 2026 Best Places to Work winner on November 4, 2025.
The company received the award in BioSpace’s small employer category and is one of 50 U.S. employers recognized (20 large, 30 small). Protara highlighted its Flatiron District, New York City office, a collaborative culture, competitive benefits, and emphasis on professional development, inclusivity, and work-life balance.
Management framed the award as recognition of employee commitment to advancing Protara’s clinical-stage programs in cancer and rare diseases and invited interest via the company careers page.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has granted inducement equity awards to a new employee. The compensation package includes 6,200 stock options at an exercise price of $4.41 per share and 3,100 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest over three years, with one-third vesting annually. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducement for employment.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has granted inducement equity awards to two new employees. The compensation package includes 6,200 stock options at an exercise price of $3.17 per share and 3,100 RSUs.
The stock options will vest over four years with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years with 33 1/3% vesting annually. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.
["Ability to attract new talent with equity compensation", "Structured vesting schedule promotes employee retention"]Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has announced its participation in two upcoming investor conferences.
The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 4, 2025, at 1:35 pm ET, and deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 9:00 am ET. Both events will take place in New York.
Webcasts of both presentations will be available on the company's investor relations website and archived for a limited time.
Protara Therapeutics (Nasdaq: TARA) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company maintains a strong financial position with $145.6 million in cash and investments, expected to fund operations into mid-2027. Key pipeline developments include:
The company plans to present interim analysis from ADVANCED-2 trial of TARA-002 in BCG-Unresponsive NMIBC patients in Q1 2026, expects to initiate patient dosing in the THRIVE-3 registrational trial of IV Choline Chloride in Q3 2025, and will provide an interim update from the STARBORN-1 Phase 2 trial of TARA-002 in pediatric LMs in Q4 2025.
Q2 2025 financial results showed a net loss of $15.0 million ($0.35 per share), with R&D expenses increasing to $10.8 million and G&A expenses rising to $5.8 million.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has granted inducement equity awards to two new employees. The compensation package includes 14,800 stock options at an exercise price of $3.06 per share and 7,400 RSUs.
The stock options will vest over four years with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years with one-third vesting annually. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.
["New talent acquisition with equity-based compensation alignment", "Structured vesting schedule promotes employee retention"]Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has announced inducement grants to two new employees. The company's Compensation Committee approved 29,500 stock options at an exercise price of $2.80 per share and 14,750 restricted stock units (RSUs) as of July 1, 2025.
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest over three years, with one-third vesting annually. Both grants are contingent on continued employment with Protara.
Catalio Capital Management has successfully closed its fourth venture fund, Catalio Nexus Fund IV, raising over $400 million in commitments. The fund, which has already made 16 investments, received significant backing from existing and new global institutional investors, RIAs, foundations, and endowments.
The firm, which manages $2 billion in assets across private equity, private credit, and public equities strategies, focuses on investing in breakthrough biomedical technology companies founded by serial scientist-entrepreneurs. Notable investments from Fund IV include co-leading PinkDx's $40 million Series A round, participating in Imperative Care's $150M Series E financing, and Alentis Therapeutics' $180M Series D round.
Fund IV has also invested in Protara Therapeutics (NASDAQ:TARA) through a PIPE transaction and launched two new companies focused on immunology and inflammation: Rhapsogen and TBD Pharma, co-founded by Catalio Venture Partners from Rockefeller University and Johns Hopkins University respectively.